Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.42 |
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | CA9 | Q16790 | 9/20 | 0.42 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA4 | P22748 | 7/20 | 0.42 |
| ▸ | CA6 | P23280 | 7/20 | 0.42 |
| ▸ | CA5A | P35218 | 7/20 | 0.42 |
| ▸ | CA7 | P43166 | 7/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8819088 | 0.79 | CA2 (0.47) | CA12CA2CA9CA1CA4 | |
| SCHEMBL1807656 | 0.72 | CA2 (0.63) | CA12CA2CA9CA1CA4 | |
| SCHEMBL10889596 | 0.72 | GAA (0.42) | CA12CA2CA9CA1CYP2C9 | |
| SCHEMBL393315 | 0.70 | CA2 (0.54) | CA12CA2CA9CA1CA4 | |
| SCHEMBL31095544 | 0.70 | CA2 (0.54) | CA12CA2CA9CA1CA4 | |
| SCHEMBL27716582 | 0.68 | TSHR (0.45) | CA12CA2CA9CA1CA7 | |
| SCHEMBL27716593 | 0.68 | LMNA (0.32) | CYP2C9CYP2C19ALDH1A1MAPTTDP1 | |
| SCHEMBL27716615 | 0.68 | TDP1 (0.45) | GLO1ALDH1A1KDM4EPKMMEN1 | |
| SCHEMBL5353740 | 0.68 | G6PD (0.56) | CA12CA2CA9CA1CA4 | |
| SCHEMBL389306 | 0.67 | CA1 (0.50) | CA12CA2CA9CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| EP-2038286-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7462611-B2 | inhibitor of HCV NS5B polymerase; to treat infections caused by hepatitis C virus; 3-(1,1-Dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-4-hydroxy-1-(3-methyl-butyl)-pyrrolo[1,2-b]pyridazin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| WO-2008073982-A2 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007150001-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | CA12 4800/4885CA2 4838/4885CA9 4776/4885 |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | CA12 4877/4885CA2 4878/4885CA9 4884/4885 |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | CA12 4877/4885CA2 4878/4885CA9 4884/4885 |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | CA12 4877/4885CA2 4878/4885CA9 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.